{"id":"NCT00857454","sponsor":"Eli Lilly and Company","briefTitle":"A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","officialTitle":"A Phase III Open-label Extension of the MTE08 Trial (A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men) to Evaluate Skin-safety","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2009-03-06","resultsPosted":"2011-01-05","lastUpdate":"2011-01-05"},"enrollment":71,"design":{"allocation":null,"model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone MD-Lotion","otherNames":["LY900011","Axiron"]}],"arms":[{"label":"Testosterone MD-lotion","type":"EXPERIMENTAL"}],"summary":"Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.","primaryOutcome":{"measure":"Change From Baseline MTE08 to MTE09 Endpoint in Draize Score","timeFrame":"Day 1, Day 190","effectByArm":[{"arm":"Testosterone MD-lotion","deltaMin":0,"sd":0.12}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":8},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":71},"commonTop":["Application site erythema","Back pain","Dry skin","Cardiac flutter","Umbilical hernia"]}}